SCHOTT Pharma AG & Co. KGaA (1SXP) - Net Assets
Based on the latest financial reports, SCHOTT Pharma AG & Co. KGaA (1SXP) has net assets worth €792.27 Million EUR (≈ $926.25 Million USD) as of September 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.44 Billion ≈ $1.69 Billion USD) and total liabilities (€650.00 Million ≈ $759.92 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 1SXP current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €792.27 Million |
| % of Total Assets | 54.93% |
| Annual Growth Rate | 25.87% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 26.53 |
SCHOTT Pharma AG & Co. KGaA - Net Assets Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's net assets have evolved over time, based on quarterly financial data. Check 1SXP tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for SCHOTT Pharma AG & Co. KGaA (2020–2024)
The table below shows the annual net assets of SCHOTT Pharma AG & Co. KGaA from 2020 to 2024. For live valuation and market cap data, see market cap of SCHOTT Pharma AG & Co. KGaA.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €792.27 Million ≈ $926.25 Million |
+14.46% |
| 2023-06-30 | €692.18 Million ≈ $809.23 Million |
-2.38% |
| 2022-06-30 | €709.04 Million ≈ $828.95 Million |
+69.05% |
| 2021-06-30 | €419.42 Million ≈ $490.34 Million |
+32.87% |
| 2020-06-30 | €315.66 Million ≈ $369.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SCHOTT Pharma AG & Co. KGaA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €790.41 Million | 100.00% |
| Total Equity | €790.41 Million | 100.00% |
SCHOTT Pharma AG & Co. KGaA Competitors by Market Cap
The table below lists competitors of SCHOTT Pharma AG & Co. KGaA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inv La Constru
SN:ILC
|
$2.40 Billion |
|
Proximus NV
BR:PROX
|
$2.40 Billion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
$2.40 Billion |
|
Coface SA
PA:COFA
|
$2.40 Billion |
|
Hand Enterprise Solutions Co
SHE:300170
|
$2.39 Billion |
|
Zhongshan Public Utilities Group Co Ltd
SHE:000685
|
$2.39 Billion |
|
Boise Cascad Llc
NYSE:BCC
|
$2.39 Billion |
|
Diamondrock Hospitality Company Common Stock
NASDAQ:DRH
|
$2.39 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SCHOTT Pharma AG & Co. KGaA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 690,431,000 to 790,406,000, a change of 99,975,000 (14.5%).
- Net income of 149,685,000 contributed positively to equity growth.
- Dividend payments of 22,592,000 reduced retained earnings.
- Other factors decreased equity by 27,118,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €149.69 Million | +18.94% |
| Dividends Paid | €22.59 Million | -2.86% |
| Other Changes | €-27.12 Million | -3.43% |
| Total Change | €- | 14.48% |
Book Value vs Market Value Analysis
This analysis compares SCHOTT Pharma AG & Co. KGaA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.49x to 4.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-06-30 | €2.09 | €21.90 | x |
| 2021-06-30 | €2.78 | €21.90 | x |
| 2022-06-30 | €4.70 | €21.90 | x |
| 2023-06-30 | €4.58 | €21.90 | x |
| 2024-06-30 | €5.25 | €21.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SCHOTT Pharma AG & Co. KGaA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.94%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.64%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.82x
- Recent ROE (18.94%) is below the historical average (21.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 24.63% | 13.26% | 0.98x | 1.90x | €46.03 Million |
| 2021 | 24.11% | 15.53% | 0.88x | 1.77x | €58.96 Million |
| 2022 | 17.73% | 15.27% | 0.69x | 1.69x | €54.65 Million |
| 2023 | 21.99% | 16.90% | 0.73x | 1.78x | €82.80 Million |
| 2024 | 18.94% | 15.64% | 0.66x | 1.82x | €70.64 Million |
Industry Comparison
This section compares SCHOTT Pharma AG & Co. KGaA's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $7,436,227,037
- Average return on equity (ROE) among peers: -8.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SCHOTT Pharma AG & Co. KGaA (1SXP) | €792.27 Million | 24.63% | 0.82x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $4.13 Billion | 6.44% | 0.93x | $15.47 Billion |
| MEDIMI AB AK (79T) | $15.25 Million | -101.01% | 0.19x | $365.27K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-1.31 Million | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $995.91 Million | 14.34% | 0.67x | $1.03 Billion |
| Carl Zeiss Meditec AG (AFX) | $1.31 Billion | 9.62% | 0.26x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.17 Billion | 13.36% | 0.40x | $2.14 Billion |
| Bio-gate AG (BIG1) | $1.55 Million | -51.89% | 1.13x | $7.12 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $17.30 Billion | 27.65% | 1.78x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $41.00 Billion | 5.75% | 0.57x | $78.07 Billion |
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a… Read more